Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line
- 30 October 1992
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 188 (2), 571-577
- https://doi.org/10.1016/0006-291x(92)91094-7
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous InfusionJNCI Journal of the National Cancer Institute, 1992
- Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase IIJournal of Molecular Biology, 1992
- A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.Journal of Clinical Oncology, 1992
- Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sitesNucleic Acids Research, 1991
- Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reactionGenomics, 1989
- Use of labeled primers in polymerase chain reaction (LP-PCR) for a rapid detection of the productNucleic Acids Research, 1989
- Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA PolymeraseScience, 1988
- Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extractionAnalytical Biochemistry, 1987